# Fulvestrant

NDC: 70860-211
Generic name: fulvestrant
Labeler / Manufacturer: Athenex Pharmaceutical Division, LLC.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Abbreviated NDA (generic)
Dosage form: INJECTION, SOLUTION
Routes: INTRAMUSCULAR
Marketing started: 20200218
Marketing ended: 20261231
FDA application: ANDA211422

## Active ingredients

- FULVESTRANT: 50 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"70860-211"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=70860-211
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8ed06e0e-c17b-4c71-8d03-888bcde4a638